is tirzepatide coming off the shortage list Bad news: You may get cut from your GLP-1 this week… FDA reconsidering its decision to

Very well written and comprehensive comparison Very informative table for RWE studies comparing tirzepoatide vs semaglutide The only addition/correction I would make is that both tirzepatide and semaglutide have trials in patients with HFpEF and both with very positive results #tirzepatide #semaglutide #obesity #type2diabetes #cardiovascularcomplications #rwe

Studies showing that semaglutide (also sold under the brand name Ozempic) can help people lose up to 15% of their bodyweight have everyone talking

Mounjaro is indicated for adults aged 18 and over with a BMI of 30 kg/m or above, or a BMI of 27 kg/m or above alongside at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol

Book a consultation with our team at Klinik Sentosa to find out if Mounjaro is right for you

Includes sample charts, dosing comparisons, safety considerations, and key guidance for individuals seeking a gentler titration approach under medical supervision.

The GLP-1 market is led by semaglutide products Ozempic and Wegovy (Novo Nordisk) and tirzepatide products Mounjaro and Zepbound (Lilly)